$B6&F18&5fJs9p=q(B


$B8&5f6hJ,(B $B0lHL8&5f(B

$B8&5f2]Bj(B

 $B%U%#%V%j%N%2%s%/%i%$%*%2%k7A@.5!9=$N2rL@(B
$B?75,!&7QB3$NJL(B $B7QB3!JJ?@.(B23$BG/EY$+$i!K(B
$B8&5fBeI= $B72GOBg3XBg3X1!9)3X8&5f2J(B
$B8&5fBeI=(B $B=Z65
$B8&5fBeI=(B $B30;35H<#(B

$B8&5fJ,C4!?=jB0!??&L>(B
$B!!(B
$B;a!!!!L>(B
$B=j!!!!B0(B
$B?&!!!!L>(B

1

 $B?\ED!!9*(B $B72GOBg3XBg3X1!(B $BGn;N2]DxA04|(B

2

 $BHSDM!!$h$7Ln(B $B72GOBg3XBg3X1!(B $BGn;N2]DxA04|(B

3

 $BMn9g@5B'(B $BKLBgDc298&(B

$B8&5fL\E*(B $B7l1U6E8G$No%H%m%s%S%s:nMQ$r2=$9$k$3$H$K$h$j%2%k2=$9$k!%0lJ}!$%U%#%V%j%N%2%s?eMO1U$r(B4$B!n0J2<$NDc292<$KGx$9$H!$%H%m%s%S%s:nMQ$r
alpa-C domain$B$H(BFragment X$B$H$N(BSPR$BB,Dj(B$B!!!!(B
$B8&5fFbMF!&@.2L(B $B%j%3%s%S%J%s%H(Balpha-C domain$B$N:n@=$H@:@=!'(B
Human Fibrinogen A$B:?$N(BC$BKvC49$7$?BgD26]3t(BAD494(DE3)$B$K$h$j!$(Balpha-C domain$B$rBgNLH/8=$5$;$?!%@:@=$O%K%C%1%k%+%i%`$rMQ$$$F9T$C$?!%(B

SPR$BB,Dj!'(B
$B%;%s%5%A%C%W$N6bI=LL$K(Balpha-C$B:?$r8GDj2=$9$k$?$a$K!$(B0.6mM 3$B!$(B 3' -Dithiobis[N-(5-amino-5-carboxypentyl)ionamide-N'$B!$(BN'-diacetic acid]dihydrochloride$B?eMO1U$K?;DR$7!$<+8JAH?%2=C1J,;RKl!J(BSAM$B!K$r7A@.$5$;$?!%?^$K(Balpgha-C domain$B$H(BFragment X$B$NAj8_:nMQ$rB,Dj$7$?(BSPR$B$NE57?E*$J(BResonance$B%+!<%V$r<($9!%(BFragment X$B$H$O!$(BFibrinogen$BJ,2r;:J*$N$&$A$N0l$D$G$"$j!$(Balpha-C domain$B$,@ZCG$5$l$?J,2r;:J*$G$"$k!%(B1$B!K$G(BSAM$B$H(Balpha-C domain$B$r7k9g$5$;$k$?$a$K%K%C%1%k$rAw1U$7$?!%(B2$B!K$G(B0.04mg/mlalpha-C domain$B?eMO1U$r%$%s%8%'%/%H$7$F6bI=LL$K8GDj2=$7!$(B3$B!K$G(B0.2mg/ml$B!!(BFragment X$B?eMO1U$r%$%s%8%'%/%H$7$?!%%7%0%J%k$NJQ2=$,8+$i$l$?$3$H$+$i!$(BFragment X$B$H(Balpa-C domain$B$,Aj8_:nMQ$7$F$$$k$3$H$,J,$+$C$?!%(B
alpa-C domain$B$H(BFragment X$B$H$N(BSPR$BB,Dj(B$B!!!!(B
$B@.2L$H$J$kO@J8!&3X2qH/I=Ey(B $BO@J8(B
1$B!K(BK. Kubota$B!$(B K. Wakamatsu$B!$(B N. Nameki$B!$(B Y. Toyama$B!$(B "Inhibition of Protein Aggregation: SAXS Study on the Role of the aC Region of Fibrinogen in the Fibrin Polymerization"$B!$(B Key Engineering Materials$B!$(B 497$B!$(B 41-46 (2012).
$B3X2qH/I=(B
1$B!KBh(B35$B2sF|K\%P%$%*%l%*%m%8!<3X2qG/2q!!?73c!!(B2012$BG/(B6$B7n(B2$BF|!I@V7l5eI=LL$H@V7l5e=89g0x;R$NAj8_:nMQ$NB,Dj!I?\ED!!9*!"30;3!!5H<#!"CfB2$B!KBh(B35$B2sF|K\%P%$%*%l%*%m%8!<3X2qG/2q!!?73c!!(B2012$BG/(B6$B7n(B2$BF|!I%U%#%V%j%s6E=8$K$*$1$k(BB$B&B:?(BN$BKvC3$B!KBh(B35$B2sF|K\%P%$%*%l%*%m%8!<3X2qG/2q!!?73c!!(B2012$BG/(B6$B7n(B1$BF|!I%U%#%V%j%N%2%s%/%i%$%*%2%k7A@.$KM?$($k%U%#%V%j%N%2%sJ,2r;:J*$*$h$S%Y%?%$%s$NE:2C8z2L!I30;3!!5H<#!"5\K\!!OB>!!3>!"Mn9g!!@5B'!%(B
4$B!KBh(B35$B2sF|K\%P%$%*%l%*%m%8!<3X2qG/2q!!?73c!!(B2012$BG/(B6$B7n(B1$BF|!I%U%#%V%j%s6E=8$K$*$1$k(BN$B7k9gE|:?$NLr3d!I7&ED!!7rFs!"J!ED!!5.9(!"EOJU!!D>8J!"30;3!!5H<#!"9TLZ!!?.0l!"Mn9g!!@5B'!%(B

$B!!(B